Disease Indications

Disease Indications 2018

Many psychiatric disorders share common neurobiological characteristics both in their etiology and clinical symptoms. This is true for disorders characterized by compulsivity, impulsivity, and disturbed attention, but also for psychiatric disorders that involve severe emotional disturbances, such as major depressive disorder, bipolar disorder, anxiety disorder and even psychotic disorders.

Therefore translational, cross-disorder studies with a life span perspective from early vulnerability to late disease chronicity may enhance our knowledge and treatment possibilities for a very large group of patients representing a serious burden to families and society as a whole.

The focus of this years conference is clinically oriented but with a strong background in preclinical neuroscience and deals in particular with the role of neuroinflammation in the etiology of psychiatric disorders and also on solutions to be found in the field neurostimuation. The vision is to gain knowledge that can be applied towards development of new treatments through collaborative efforts.

Disease Indications 2013-2017


In previous conferences TN2 covered neurodegenerative disorders, particularly Alzheimer’s disease (AD), other forms of dementia and Parkinson’s disease (PD), are among the biggest health care challenges of the 21st century. Neurodegenerative disorders share a profound pathophysiological and clinical complexity. For the majority of patients, multiple causes in concert lead to the development of disease, which unfolds over the course of years, probably decades. A careful clinical evaluation is the corner stone for a valid diagnosis of any neurodegenerative disorder.
Moreover, it provides fundamental insight into the basic mechanisms that are critical for the development and validation of animal models and biomarkers. To date, treatment is limited to alleviation of symptoms, but our ultimate goal is to recognize disease before it manifests clinically, understand disease mechanisms and subsequently modify the disease process to prevent progression to a full blown disease state.
At TN2 it was discussed how we can improve early diagnostics, understand the clinical heterogeneity and mixed pathologies, and unravel the underlying mechanisms in patients and relevant model systems.

Neuroinfection and -inflammation

In parallel during the 2017 TN2 confence, we covered neuroinfection and –inflammation. The focus was on Multiple Sclerosis, meningitis & encephalitis, and inflammatory neuropathies. In these areas, VUmc/VU (MS Center Amsterdam) and AMC (Neuroinfections Amsterdam) have leading roles both national and international, both from a clinical and a research perspective. Research on the blood-brain-barrier, a crucial dominator of multiple sclerosis and meningitis, was strongly encouraged. Innovative projects outside these areas of primary interest were also welcomed, though.
Translational research presented included integrative approaches running from bedside to molecule and vice versa.